Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

VRDN holding history

Viridian Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

VRDN overviewAll 13F holders of VRDNFull Q2 2026 holdings

Shares (Q2 2026)
1,428,843
Value
$26.2M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of VRDN by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,428,843$26.2M<0.1%+1,121,709+365.2%AddedHolders
Q1 2026307,134$6.01M<0.1%+142,314+86.3%AddedHolders
Q4 2025164,820$5.13M<0.1%−282,857−63.2%ReducedHolders
Q3 2025447,677$9.66M<0.1%−85,966−16.1%ReducedHolders
Q2 2025533,643$7.46M<0.1%+29,458+5.8%AddedHolders
Q1 2025504,185$6.80M<0.1%−7,886−1.5%ReducedHolders
Q4 2024512,071$9.82M<0.1%+427,338+504.3%AddedHolders
Q3 202484,733$1.93M<0.1%−145,643−63.2%ReducedHolders
Q2 2024230,376$3.00M<0.1%−149,208−39.3%ReducedHolders
Q1 2024379,584$6.65M<0.1%+236,198+164.7%AddedHolders
Q4 2023143,386$3.12M<0.1%+74,970+109.6%AddedHolders
Q3 202368,416$1.05M<0.1%−11,165−14.0%ReducedHolders
Q2 202379,581$1.89M<0.1%+10,790+15.7%AddedHolders
Q1 202368,791$1.75M<0.1%−76,987−52.8%ReducedHolders
Q4 2022145,778$4.26M<0.1%+96,481+195.7%AddedHolders
Q3 202249,297$1.01M<0.1%+49,284+379,107.7%AddedHolders
Q2 202213$00.0%−209−94.1%ReducedHolders
Q1 2022222$4.00K<0.1%+209+1,607.7%AddedHolders
Q4 202113$00.0%−1,430−99.1%ReducedHolders
Q3 20211,443$24.0K<0.1%+1,430+11,000.0%AddedHolders
Q2 202113$00.0%00.0%UnchangedHolders
Q1 202113$00.0%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.